Human VEGF (Bevacizumab) Antibody Summary
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF (Bevacizumab) Antibody. Recombinant Human VEGF165 (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human VEGF165 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab) Monoclonal Antibody (Catalog # MAB9947). The ND50 is typically 10-80 ng/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C, as supplied.
- 1 month, 2 to 8 °C under sterile conditions after opening.
- 6 months, -20 to -70 °C under sterile conditions after opening.
Bevacizumab is a biosimilar directed against VEGF. This product can be used as the standard in pharmacokinetic (PK) assays.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human VEGF (Bevacizumab) Antibody
There are currently no reviews for this product. Be the first to review Human VEGF (Bevacizumab) Antibody and earn rewards!
Have you used Human VEGF (Bevacizumab) Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image